Iovance Biotherapeutics Statistics

Total Valuation

LON:0JDK has a market cap or net worth of GBP 462.61 million. The enterprise value is 235.93 million.

Market Cap	462.61M
Enterprise Value	235.93M

Important Dates

The next estimated earnings date is Thursday, August 7, 2025.

Earnings Date	Aug 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	333.93M
Shares Outstanding	n/a
Shares Change (YoY)	+22.47%
Shares Change (QoQ)	+5.90%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	280.26M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.81
PB Ratio	0.78
P/TBV Ratio	1.24
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.81
EV / Sales	1.50
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.88

Financial Position

The company has a current ratio of 4.18, with a Debt / Equity ratio of 0.07.

Current Ratio	4.18
Quick Ratio	3.51
Debt / Equity	0.07
Debt / EBITDA	n/a
Debt / FCF	-0.15
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -51.85% and return on invested capital (ROIC) is -31.43%.

Return on Equity (ROE)	-51.85%
Return on Assets (ROA)	-27.14%
Return on Invested Capital (ROIC)	-31.43%
Return on Capital Employed (ROCE)	-47.25%
Revenue Per Employee	196,434
Profits Per Employee	-346,692
Employee Count	838
Asset Turnover	0.23
Inventory Turnover	4.00

Taxes

Income Tax	-2.52M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -75.20% in the last 52 weeks. The beta is 0.86, so LON:0JDK's price volatility has been lower than the market average.

Beta (5Y)	0.86
52-Week Price Change	-75.20%
50-Day Moving Average	2.09
200-Day Moving Average	5.68
Relative Strength Index (RSI)	48.60
Average Volume (20 Days)	85,821

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	7.16

Income Statement

In the last 12 months, LON:0JDK had revenue of GBP 164.61 million and -290.53 million in losses. Loss per share was -0.96.

Revenue	164.61M
Gross Profit	35.76M
Operating Income	-308.65M
Pretax Income	-293.05M
Net Income	-290.53M
EBITDA	-282.52M
EBIT	-308.65M
Loss Per Share	-0.96

Full Income Statement

Balance Sheet

The company has 278.41 million in cash and 41.58 million in debt, giving a net cash position of 236.84 million.

Cash & Cash Equivalents	278.41M
Total Debt	41.58M
Net Cash	236.84M
Net Cash Per Share	n/a
Equity (Book Value)	594.32M
Book Value Per Share	1.78
Working Capital	301.82M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -258.82 million and capital expenditures -10.15 million, giving a free cash flow of -268.96 million.

Operating Cash Flow	-258.82M
Capital Expenditures	-10.15M
Free Cash Flow	-268.96M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 21.72%, with operating and profit margins of -187.50% and -176.49%.

Gross Margin	21.72%
Operating Margin	-187.50%
Pretax Margin	-178.03%
Profit Margin	-176.49%
EBITDA Margin	-171.63%
EBIT Margin	-187.50%
FCF Margin	n/a

Dividends & Yields

LON:0JDK does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-22.47%
Shareholder Yield	n/a
Earnings Yield	-62.80%
FCF Yield	-58.14%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0JDK has an Altman Z-Score of 3.47 and a Piotroski F-Score of 3.

Altman Z-Score	3.47
Piotroski F-Score	3